moneyheap
ELV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Elevance Health, Inc. (ELV) stock moving?
Elevance's most recent company event is a Nov 10 Regulation FD filing in which officers will reaffirm FY2026 guidance: GAAP EPS of at least $22.00 with about $7.00 of net unfavorable items, adjusted EPS of at least $29.00, and a 90.2% benefit expense ratio (±50 bp). This is a reaffirmation, not a raise or cut, so it removes downside guidance risk but adds no new upside. The stock closed at $429.65 on Nov 10, up 2.7% from $418.25 on Nov 9, but still below the $445.28 close on Oct 22 and the $448.54 intraday high on Nov 5. Since Oct 22 the shares have traded in a roughly $407–$449 range. Volume was heavy on Nov 2 (2.18M shares as the stock hit $406.90) and Nov 5 (2.11M shares on the rebound high), versus a 14-day average near 1.4M. Volume on Nov 10 was lighter at 907K shares, so the rebound lacks broad confirmation. Analyst sentiment softened, with Evercore ISI cutting its target to $440 from $460 on Oct 28. The mixed shelf filing (Oct 28–29) adds potential future dilution with no terms disclosed. Policy headlines cut both ways: a Labor Department rule requiring PBM pay disclosure is a regulatory headwind, while Democratic state election wins that could expand Medicaid for over a million people are a possible member-growth tailwind. The insider sale of about $572K and the political contribution disclosure are minor.
News behind the analysis
- Elevance Health Reaffirms Full Year 2026 Guidance Ahead of Investor MeetingsIn a Regulation FD 8-K, officers said they will reaffirm FY2026 GAAP EPS of at least $22.00 (including about $7.00 of net unfavorable items), adjusted EPS of at least $29.00, and a 90.2% benefit expense ratio (±50 bp).
- 'State Democratic wins make Medicaid expansion a possibility for more than a million people' - STAT NewsDemocratic state election wins raise the possibility of Medicaid expansion for more than a million additional people, a potential member-growth tailwind for Medicaid-exposed insurers.
- Elevance Health Executive Sells Shares Worth $572,000Executive Lavu Ratnakar sold 1,300 shares, disclosed in an SEC filing; the sale is small relative to the company's share count.
- Elevance Health Inc. Discloses Political Contributions to Leadership CommitteesElevance made political contributions to leadership committees for gubernatorial candidates in September 2026, a routine disclosure with limited direct financial impact.
- Elevance Health Files for Mixed Shelf OfferingElevance filed a mixed shelf registration that allows future issuance of various securities; no offering size or terms were disclosed.
- Elevance Health Files Prospectus For Mixed Shelf Offering; Terms Not DisclosedThe prospectus for the mixed shelf offering was filed with terms not disclosed, which keeps potential future share issuance as an open question for investors.
- Evercore ISI Adjusts Price Target on Elevance Health to $440 From $460Evercore ISI lowered its price target on Elevance from $460 to $440, a negative analyst revision after the stock's post-earnings move.
- 'Drug Middlemen Will Soon Have to Share Details on How They Are Paid; New Labor Department regulation will require pharmacy-benefit managers to disclose information to employers' - WSJ ExclusiveA new Labor Department rule will require pharmacy-benefit managers to disclose how they are paid to employers, adding regulatory pressure on the PBM business that Elevance's pharmacy arm is part of.
- Elevance Health Reports Third Quarter 2026 Results (Form 8-K, Item 2.02)Elevance furnished its Q3 2026 earnings press release (Exhibit 99.1) under Item 2.02, the basis for the current FY2026 guidance being reaffirmed.
About Elevance Health, Inc.
Elevance Health, based in Indianapolis and formerly called Anthem, is one of the largest US health insurers, with about 45 million medical members. It runs Anthem Blue Cross Blue Shield plans in 14 states, and its Carelon unit sells pharmacy benefits, home care, behavioral health and other services to its own plans and to outside customers.
How it makes money
Most of its money comes from insurance premiums in its Health Benefits segment, which covers employer group plans, individual ACA plans, Medicare Advantage, Medicaid and the Federal Employee Program. That segment brought in about $43 billion in operating revenue in Q3 2026. It also earns fees for running health plans that employers pay for themselves. Carelon added about $19 billion in Q3 2026, mostly from CarelonRx pharmacy benefit revenue and fees for care services, and part of that is business with Elevance's own plans. Total operating revenue was about $50 billion that quarter. Profit depends on how much of its premiums it pays out in medical claims, which the company expected to be about 90% for 2026.
What usually moves ELV
- Medical cost trends and how much members use care
- Medicaid and Medicare Advantage government rates and risk-adjustment rules
- Membership changes in ACA, Medicaid and employer plans
- Health care policy and regulatory scrutiny
- Growth and margins at Carelon and CarelonRx